Marian Rewers
Concepts (919)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 377 | 2025 | 3715 | 20.600 |
Why?
| | Autoimmunity | 129 | 2025 | 908 | 11.660 |
Why?
| | Islets of Langerhans | 117 | 2025 | 803 | 11.450 |
Why?
| | Autoantibodies | 181 | 2025 | 1496 | 11.040 |
Why?
| | Celiac Disease | 52 | 2024 | 294 | 7.100 |
Why?
| | Genetic Predisposition to Disease | 91 | 2025 | 2426 | 4.070 |
Why?
| | Coronary Artery Disease | 34 | 2018 | 698 | 3.420 |
Why?
| | Diabetic Angiopathies | 28 | 2017 | 259 | 3.180 |
Why?
| | Child, Preschool | 198 | 2025 | 11074 | 2.910 |
Why?
| | Calcinosis | 23 | 2015 | 235 | 2.890 |
Why?
| | HLA-DQ Antigens | 37 | 2020 | 181 | 2.830 |
Why?
| | HLA-DR Antigens | 28 | 2021 | 228 | 2.760 |
Why?
| | Child | 228 | 2025 | 21935 | 2.730 |
Why?
| | Insulin Resistance | 55 | 2018 | 1208 | 2.650 |
Why?
| | Insulin | 74 | 2025 | 2409 | 2.490 |
Why?
| | Infant | 165 | 2025 | 9465 | 2.440 |
Why?
| | Disease Progression | 80 | 2024 | 2757 | 2.420 |
Why?
| | Risk Factors | 161 | 2025 | 10388 | 2.200 |
Why?
| | Humans | 496 | 2025 | 137585 | 2.130 |
Why?
| | Blood Glucose | 38 | 2022 | 2186 | 2.120 |
Why?
| | Transglutaminases | 29 | 2024 | 156 | 2.070 |
Why?
| | Genotype | 62 | 2023 | 1916 | 1.990 |
Why?
| | Diabetic Ketoacidosis | 14 | 2025 | 201 | 1.990 |
Why?
| | Prospective Studies | 98 | 2024 | 7604 | 1.920 |
Why?
| | Male | 334 | 2025 | 67762 | 1.920 |
Why?
| | Female | 342 | 2025 | 73304 | 1.860 |
Why?
| | Polymorphism, Single Nucleotide | 36 | 2025 | 2189 | 1.760 |
Why?
| | Adolescent | 136 | 2025 | 21513 | 1.740 |
Why?
| | Insulin Antibodies | 23 | 2024 | 105 | 1.690 |
Why?
| | Biomarkers | 46 | 2023 | 4149 | 1.680 |
Why?
| | Mass Screening | 22 | 2025 | 1287 | 1.660 |
Why?
| | Diabetic Nephropathies | 19 | 2020 | 294 | 1.650 |
Why?
| | Insulin-Secreting Cells | 15 | 2023 | 377 | 1.540 |
Why?
| | Hyperglycemia | 10 | 2024 | 347 | 1.490 |
Why?
| | Coronary Disease | 15 | 2010 | 385 | 1.490 |
Why?
| | Glutamate Decarboxylase | 34 | 2023 | 170 | 1.480 |
Why?
| | Prediabetic State | 14 | 2023 | 253 | 1.460 |
Why?
| | Diet | 29 | 2024 | 1278 | 1.370 |
Why?
| | Autoimmune Diseases | 16 | 2019 | 460 | 1.340 |
Why?
| | Case-Control Studies | 57 | 2023 | 3556 | 1.340 |
Why?
| | Health Care Costs | 2 | 2025 | 398 | 1.250 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 10 | 2022 | 46 | 1.240 |
Why?
| | HLA Antigens | 24 | 2025 | 240 | 1.240 |
Why?
| | Follow-Up Studies | 62 | 2024 | 5131 | 1.210 |
Why?
| | Glutens | 11 | 2023 | 60 | 1.200 |
Why?
| | Fatty Acids, Omega-3 | 8 | 2020 | 140 | 1.130 |
Why?
| | Cohort Studies | 66 | 2022 | 5742 | 1.120 |
Why?
| | Enterovirus Infections | 6 | 2023 | 177 | 1.080 |
Why?
| | Diabetes Mellitus, Type 2 | 35 | 2023 | 2531 | 1.080 |
Why?
| | Adult | 158 | 2025 | 37929 | 1.070 |
Why?
| | Polymorphism, Genetic | 15 | 2019 | 660 | 1.050 |
Why?
| | Environment | 5 | 2018 | 358 | 1.030 |
Why?
| | H(+)-K(+)-Exchanging ATPase | 2 | 2017 | 15 | 0.990 |
Why?
| | Erythrocyte Membrane | 5 | 2015 | 55 | 0.980 |
Why?
| | Infant, Newborn | 64 | 2025 | 6079 | 0.960 |
Why?
| | Middle Aged | 137 | 2025 | 33479 | 0.920 |
Why?
| | Atherosclerosis | 15 | 2018 | 415 | 0.910 |
Why?
| | Colorado | 44 | 2024 | 4565 | 0.900 |
Why?
| | Diabetes Complications | 7 | 2019 | 227 | 0.860 |
Why?
| | Coronary Vessels | 8 | 2017 | 248 | 0.860 |
Why?
| | Incidence | 36 | 2022 | 2804 | 0.850 |
Why?
| | Albuminuria | 12 | 2016 | 185 | 0.850 |
Why?
| | Enterovirus | 5 | 2019 | 86 | 0.850 |
Why?
| | HLA-DR3 Antigen | 16 | 2023 | 80 | 0.830 |
Why?
| | Proportional Hazards Models | 26 | 2024 | 1266 | 0.820 |
Why?
| | Longitudinal Studies | 28 | 2025 | 2844 | 0.820 |
Why?
| | DNA Methylation | 6 | 2025 | 643 | 0.810 |
Why?
| | Vascular Calcification | 9 | 2018 | 108 | 0.800 |
Why?
| | Age of Onset | 18 | 2025 | 518 | 0.790 |
Why?
| | Predictive Value of Tests | 25 | 2019 | 2031 | 0.770 |
Why?
| | Glucose Tolerance Test | 26 | 2022 | 366 | 0.730 |
Why?
| | Young Adult | 51 | 2025 | 13209 | 0.720 |
Why?
| | C-Peptide | 7 | 2025 | 163 | 0.720 |
Why?
| | Breast Feeding | 18 | 2021 | 440 | 0.700 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 12 | 2025 | 63 | 0.690 |
Why?
| | HLA-DR4 Antigen | 16 | 2022 | 78 | 0.690 |
Why?
| | Genetic Testing | 8 | 2019 | 460 | 0.690 |
Why?
| | Fatty Acids | 6 | 2021 | 443 | 0.680 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2022 | 641 | 0.670 |
Why?
| | Calcium | 8 | 2023 | 1199 | 0.660 |
Why?
| | Antibodies, Viral | 6 | 2023 | 625 | 0.650 |
Why?
| | Haplotypes | 14 | 2025 | 494 | 0.630 |
Why?
| | Autoantigens | 9 | 2025 | 430 | 0.630 |
Why?
| | Vitamin D | 7 | 2018 | 397 | 0.620 |
Why?
| | Zinc Transporter 8 | 7 | 2021 | 87 | 0.600 |
Why?
| | Prevalence | 23 | 2024 | 2734 | 0.590 |
Why?
| | Early Diagnosis | 7 | 2025 | 242 | 0.590 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2021 | 146 | 0.590 |
Why?
| | Seroconversion | 6 | 2021 | 46 | 0.580 |
Why?
| | Uric Acid | 6 | 2018 | 163 | 0.580 |
Why?
| | Cross-Sectional Studies | 36 | 2025 | 5472 | 0.580 |
Why?
| | GTP-Binding Proteins | 7 | 2024 | 161 | 0.570 |
Why?
| | Germany | 12 | 2024 | 121 | 0.550 |
Why?
| | Infant Food | 7 | 2018 | 65 | 0.550 |
Why?
| | Logistic Models | 24 | 2017 | 2074 | 0.550 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2016 | 99 | 0.530 |
Why?
| | Adiponectin | 5 | 2016 | 244 | 0.530 |
Why?
| | Fibrinogen | 5 | 2019 | 168 | 0.530 |
Why?
| | Edible Grain | 4 | 2008 | 49 | 0.520 |
Why?
| | Smoking | 9 | 2025 | 1627 | 0.520 |
Why?
| | Metabolomics | 5 | 2021 | 678 | 0.520 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 275 | 0.510 |
Why?
| | Glomerular Filtration Rate | 15 | 2020 | 746 | 0.510 |
Why?
| | Arteriosclerosis | 17 | 2004 | 88 | 0.500 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2013 | 430 | 0.490 |
Why?
| | Hypoglycemia | 5 | 2014 | 445 | 0.490 |
Why?
| | Lipids | 5 | 2019 | 672 | 0.490 |
Why?
| | Inflammation | 8 | 2017 | 2837 | 0.480 |
Why?
| | Sensitivity and Specificity | 21 | 2022 | 1946 | 0.480 |
Why?
| | Prenatal Exposure Delayed Effects | 7 | 2025 | 605 | 0.470 |
Why?
| | Triglycerides | 13 | 2020 | 524 | 0.470 |
Why?
| | Age Factors | 37 | 2022 | 3295 | 0.470 |
Why?
| | Luminescent Measurements | 4 | 2021 | 76 | 0.460 |
Why?
| | Milk | 7 | 2017 | 124 | 0.460 |
Why?
| | Finland | 15 | 2024 | 85 | 0.460 |
Why?
| | Environmental Exposure | 4 | 2025 | 579 | 0.460 |
Why?
| | Hypertension | 11 | 2021 | 1295 | 0.460 |
Why?
| | Probiotics | 3 | 2022 | 54 | 0.450 |
Why?
| | C-Reactive Protein | 5 | 2018 | 410 | 0.450 |
Why?
| | Genome-Wide Association Study | 9 | 2025 | 1431 | 0.450 |
Why?
| | Helicobacter Infections | 1 | 2014 | 32 | 0.450 |
Why?
| | Helicobacter pylori | 1 | 2014 | 42 | 0.440 |
Why?
| | Risk | 17 | 2020 | 912 | 0.440 |
Why?
| | Time Factors | 21 | 2018 | 6828 | 0.430 |
Why?
| | Antibodies | 5 | 2024 | 410 | 0.430 |
Why?
| | Body Mass Index | 22 | 2023 | 2389 | 0.430 |
Why?
| | Asymptomatic Diseases | 3 | 2023 | 89 | 0.420 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2014 | 54 | 0.420 |
Why?
| | Dietary Supplements | 7 | 2024 | 561 | 0.420 |
Why?
| | Sweden | 13 | 2024 | 101 | 0.420 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 32 | 0.420 |
Why?
| | Immunogenetics | 1 | 2013 | 7 | 0.410 |
Why?
| | Dyslipidemias | 4 | 2015 | 176 | 0.410 |
Why?
| | Alleles | 14 | 2021 | 891 | 0.410 |
Why?
| | Glucose Clamp Technique | 8 | 2020 | 195 | 0.400 |
Why?
| | Risk Assessment | 17 | 2021 | 3457 | 0.400 |
Why?
| | United States | 35 | 2025 | 14841 | 0.400 |
Why?
| | Bacteriophages | 2 | 2025 | 98 | 0.400 |
Why?
| | Prognosis | 17 | 2021 | 4030 | 0.400 |
Why?
| | HLA-D Antigens | 5 | 2019 | 34 | 0.390 |
Why?
| | Dietary Fats | 3 | 2014 | 304 | 0.390 |
Why?
| | Oxylipins | 3 | 2023 | 40 | 0.390 |
Why?
| | Child Nutritional Physiological Phenomena | 4 | 2019 | 108 | 0.380 |
Why?
| | Fasting | 12 | 2015 | 281 | 0.380 |
Why?
| | Epitopes | 6 | 2025 | 479 | 0.370 |
Why?
| | Vitamin D Deficiency | 2 | 2011 | 186 | 0.370 |
Why?
| | Lipoproteins | 4 | 2015 | 168 | 0.370 |
Why?
| | Apolipoproteins A | 2 | 2006 | 19 | 0.370 |
Why?
| | Ascorbic Acid | 4 | 2023 | 177 | 0.360 |
Why?
| | Addison Disease | 6 | 2012 | 43 | 0.360 |
Why?
| | Liver | 3 | 2012 | 1943 | 0.350 |
Why?
| | Hypoglycemic Agents | 8 | 2020 | 1291 | 0.350 |
Why?
| | Fetal Blood | 6 | 2021 | 327 | 0.350 |
Why?
| | Sex Factors | 20 | 2020 | 2071 | 0.350 |
Why?
| | Adipocytes | 1 | 2012 | 222 | 0.350 |
Why?
| | Life Style | 5 | 2015 | 490 | 0.340 |
Why?
| | Hypolipidemic Agents | 2 | 2010 | 91 | 0.340 |
Why?
| | Dietary Proteins | 4 | 2019 | 135 | 0.340 |
Why?
| | Cholesterol, HDL | 8 | 2015 | 203 | 0.340 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 591 | 0.330 |
Why?
| | Precision Medicine | 1 | 2014 | 429 | 0.330 |
Why?
| | Plant Proteins | 1 | 2011 | 113 | 0.330 |
Why?
| | Epidemics | 1 | 2011 | 89 | 0.330 |
Why?
| | Surveys and Questionnaires | 17 | 2024 | 5778 | 0.330 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 740 | 0.330 |
Why?
| | Research | 2 | 2013 | 451 | 0.330 |
Why?
| | Eating | 5 | 2023 | 380 | 0.330 |
Why?
| | Patient Education as Topic | 2 | 2005 | 766 | 0.320 |
Why?
| | Cesarean Section | 2 | 2024 | 184 | 0.320 |
Why?
| | Blood Proteins | 3 | 2017 | 252 | 0.320 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2025 | 1091 | 0.320 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 30 | 0.320 |
Why?
| | CTLA-4 Antigen | 5 | 2017 | 99 | 0.320 |
Why?
| | HLA-DQ beta-Chains | 12 | 2019 | 63 | 0.320 |
Why?
| | Obesity | 12 | 2015 | 2992 | 0.310 |
Why?
| | Cystatin C | 6 | 2014 | 65 | 0.310 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1050 | 0.310 |
Why?
| | Family Health | 8 | 2017 | 196 | 0.310 |
Why?
| | Multivariate Analysis | 10 | 2016 | 1509 | 0.300 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 697 | 0.300 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 37 | 0.300 |
Why?
| | Major Histocompatibility Complex | 5 | 2011 | 227 | 0.300 |
Why?
| | Sex Distribution | 6 | 2011 | 375 | 0.300 |
Why?
| | Rotavirus | 2 | 2016 | 20 | 0.300 |
Why?
| | Antigens, CD | 2 | 2009 | 521 | 0.290 |
Why?
| | Feces | 7 | 2025 | 484 | 0.290 |
Why?
| | Reproductive History | 1 | 2008 | 17 | 0.290 |
Why?
| | Diabetes Mellitus | 8 | 2009 | 1040 | 0.290 |
Why?
| | Europe | 11 | 2021 | 414 | 0.280 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.280 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.280 |
Why?
| | Pregnancy | 18 | 2025 | 6763 | 0.280 |
Why?
| | Adiposity | 7 | 2020 | 518 | 0.280 |
Why?
| | Tomography, X-Ray Computed | 12 | 2018 | 2691 | 0.270 |
Why?
| | Seroepidemiologic Studies | 4 | 2023 | 165 | 0.270 |
Why?
| | Diet, Gluten-Free | 3 | 2024 | 45 | 0.270 |
Why?
| | Reference Values | 10 | 2012 | 816 | 0.270 |
Why?
| | Iron | 3 | 2023 | 313 | 0.270 |
Why?
| | Gene-Environment Interaction | 5 | 2024 | 192 | 0.260 |
Why?
| | Survival Analysis | 4 | 2021 | 1325 | 0.260 |
Why?
| | Glycopeptides | 2 | 2018 | 43 | 0.260 |
Why?
| | Adipose Tissue | 4 | 2018 | 635 | 0.260 |
Why?
| | Respiratory Tract Infections | 4 | 2017 | 390 | 0.260 |
Why?
| | Metabolome | 2 | 2020 | 350 | 0.260 |
Why?
| | HLA-DRB1 Chains | 8 | 2019 | 112 | 0.260 |
Why?
| | Exercise | 4 | 2023 | 2057 | 0.260 |
Why?
| | Patient Compliance | 3 | 2023 | 581 | 0.260 |
Why?
| | RNA, Viral | 3 | 2019 | 656 | 0.260 |
Why?
| | Overweight | 3 | 2021 | 558 | 0.260 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 85 | 0.260 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2011 | 203 | 0.260 |
Why?
| | Rotavirus Infections | 1 | 2006 | 43 | 0.260 |
Why?
| | Remission Induction | 2 | 2004 | 288 | 0.250 |
Why?
| | Apolipoproteins C | 1 | 2006 | 4 | 0.250 |
Why?
| | Proteomics | 5 | 2021 | 1111 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 201 | 0.250 |
Why?
| | Contraception | 1 | 2008 | 161 | 0.250 |
Why?
| | Regression Analysis | 15 | 2014 | 1024 | 0.250 |
Why?
| | Infant Formula | 3 | 2019 | 75 | 0.250 |
Why?
| | Aged | 45 | 2021 | 23961 | 0.240 |
Why?
| | Protein Tyrosine Phosphatases | 7 | 2006 | 172 | 0.240 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 66 | 0.240 |
Why?
| | Cardiovascular Diseases | 8 | 2018 | 2111 | 0.240 |
Why?
| | Maternal Age | 3 | 2004 | 129 | 0.240 |
Why?
| | Gene Frequency | 10 | 2020 | 521 | 0.240 |
Why?
| | Diet Records | 4 | 2019 | 83 | 0.240 |
Why?
| | Carotid Arteries | 5 | 1998 | 206 | 0.240 |
Why?
| | Proinsulin | 3 | 2014 | 54 | 0.230 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2025 | 15 | 0.230 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2011 | 367 | 0.230 |
Why?
| | Apolipoproteins | 3 | 2014 | 33 | 0.230 |
Why?
| | Glucose Intolerance | 7 | 2013 | 146 | 0.230 |
Why?
| | Plasminogen Activator Inhibitor 1 | 6 | 2017 | 86 | 0.230 |
Why?
| | Abdominal Wall | 1 | 2004 | 24 | 0.230 |
Why?
| | Tobacco Smoke Pollution | 4 | 2019 | 261 | 0.230 |
Why?
| | Immunotherapy | 1 | 2009 | 641 | 0.230 |
Why?
| | Docosahexaenoic Acids | 3 | 2021 | 84 | 0.230 |
Why?
| | Linear Models | 7 | 2016 | 849 | 0.220 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 494 | 0.220 |
Why?
| | Health Surveys | 3 | 2018 | 514 | 0.220 |
Why?
| | Hyperlipidemias | 1 | 2005 | 120 | 0.220 |
Why?
| | Immunoglobulin A | 6 | 2024 | 211 | 0.220 |
Why?
| | Delivery, Obstetric | 2 | 2004 | 144 | 0.220 |
Why?
| | Animals | 26 | 2022 | 36940 | 0.210 |
Why?
| | Bone Density | 2 | 2020 | 489 | 0.210 |
Why?
| | Haptoglobins | 3 | 2013 | 53 | 0.210 |
Why?
| | Seasons | 5 | 2024 | 547 | 0.210 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 54 | 0.210 |
Why?
| | Vitamin B Complex | 1 | 2024 | 44 | 0.210 |
Why?
| | Coronary Angiography | 2 | 2014 | 317 | 0.210 |
Why?
| | Peptide Library | 1 | 2024 | 92 | 0.210 |
Why?
| | Alanine Transaminase | 2 | 2015 | 157 | 0.210 |
Why?
| | Genetic Variation | 3 | 2021 | 991 | 0.210 |
Why?
| | Birth Weight | 4 | 2016 | 516 | 0.210 |
Why?
| | Iron Overload | 1 | 2023 | 17 | 0.200 |
Why?
| | Child Development | 2 | 2020 | 475 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 382 | 0.200 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 1724 | 0.200 |
Why?
| | ROC Curve | 4 | 2019 | 554 | 0.200 |
Why?
| | Virus Diseases | 4 | 2021 | 212 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 889 | 0.200 |
Why?
| | Diabetic Retinopathy | 4 | 2016 | 189 | 0.190 |
Why?
| | Ketone Bodies | 2 | 2014 | 14 | 0.190 |
Why?
| | Alcohol Drinking | 1 | 2009 | 828 | 0.190 |
Why?
| | Pediatrics | 4 | 2020 | 1101 | 0.190 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 213 | 0.190 |
Why?
| | Mothers | 4 | 2021 | 754 | 0.190 |
Why?
| | Influenza, Human | 2 | 2022 | 622 | 0.190 |
Why?
| | Micronutrients | 2 | 2017 | 92 | 0.190 |
Why?
| | Lipid Metabolism | 2 | 2019 | 518 | 0.190 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2021 | 176 | 0.190 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 445 | 0.190 |
Why?
| | Peptides | 3 | 2024 | 985 | 0.190 |
Why?
| | Parents | 6 | 2023 | 1347 | 0.190 |
Why?
| | Lipase | 1 | 2002 | 69 | 0.180 |
Why?
| | Chromosome Mapping | 3 | 2021 | 523 | 0.180 |
Why?
| | Age Distribution | 5 | 2011 | 392 | 0.180 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2021 | 13 | 0.180 |
Why?
| | T-Lymphocytes | 3 | 2025 | 1996 | 0.180 |
Why?
| | Odds Ratio | 6 | 2015 | 1070 | 0.180 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2021 | 46 | 0.180 |
Why?
| | Reproducibility of Results | 9 | 2021 | 3284 | 0.180 |
Why?
| | Monitoring, Ambulatory | 2 | 2014 | 87 | 0.180 |
Why?
| | Glycerol | 2 | 2012 | 94 | 0.180 |
Why?
| | Body Height | 3 | 2014 | 199 | 0.180 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 55 | 0.180 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1250 | 0.180 |
Why?
| | Blood Pressure | 9 | 2014 | 1786 | 0.180 |
Why?
| | Growth | 2 | 2016 | 60 | 0.180 |
Why?
| | Mass Spectrometry | 3 | 2021 | 739 | 0.180 |
Why?
| | White Matter | 1 | 2023 | 145 | 0.180 |
Why?
| | Polysaccharides | 2 | 2022 | 79 | 0.180 |
Why?
| | Gestational Age | 3 | 2020 | 910 | 0.180 |
Why?
| | Bacteria | 2 | 2025 | 858 | 0.170 |
Why?
| | F2-Isoprostanes | 2 | 2015 | 21 | 0.170 |
Why?
| | Gastroenteritis | 2 | 2016 | 69 | 0.170 |
Why?
| | Luminescence | 3 | 2016 | 38 | 0.170 |
Why?
| | HLA-B8 Antigen | 4 | 2012 | 14 | 0.170 |
Why?
| | Vitamins | 2 | 2020 | 185 | 0.170 |
Why?
| | Ketosis | 1 | 2020 | 12 | 0.170 |
Why?
| | Influenza Vaccines | 2 | 2017 | 539 | 0.170 |
Why?
| | Genomics | 2 | 2021 | 795 | 0.170 |
Why?
| | Neonatal Screening | 4 | 2020 | 169 | 0.160 |
Why?
| | Dietary Sucrose | 1 | 2020 | 49 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2015 | 155 | 0.160 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 15 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 24 | 0.160 |
Why?
| | Disease Susceptibility | 6 | 2020 | 347 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 41 | 0.160 |
Why?
| | Biopsy | 5 | 2017 | 1129 | 0.160 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 113 | 0.160 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 601 | 0.160 |
Why?
| | Energy Intake | 5 | 2023 | 485 | 0.160 |
Why?
| | Life Change Events | 1 | 2021 | 151 | 0.160 |
Why?
| | Interferon-gamma | 2 | 2021 | 789 | 0.160 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 79 | 0.160 |
Why?
| | Developing Countries | 2 | 1993 | 307 | 0.160 |
Why?
| | Kidney | 2 | 2018 | 1468 | 0.160 |
Why?
| | Oxidative Stress | 3 | 2017 | 1317 | 0.160 |
Why?
| | Metabolic Clearance Rate | 3 | 2014 | 115 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 223 | 0.160 |
Why?
| | Epidemiologic Methods | 4 | 2014 | 97 | 0.150 |
Why?
| | Iodide Peroxidase | 5 | 2025 | 28 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2003 | 394 | 0.150 |
Why?
| | Apolipoproteins B | 2 | 2015 | 43 | 0.150 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 852 | 0.150 |
Why?
| | Measles | 1 | 2019 | 46 | 0.150 |
Why?
| | Cation Transport Proteins | 3 | 2011 | 134 | 0.150 |
Why?
| | Butyrates | 1 | 2019 | 61 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 60 | 0.150 |
Why?
| | Glycosuria | 2 | 2009 | 9 | 0.150 |
Why?
| | Fatty Acids, Omega-6 | 4 | 2020 | 48 | 0.150 |
Why?
| | Cotinine | 1 | 2019 | 77 | 0.150 |
Why?
| | Antibodies, Bacterial | 1 | 2019 | 146 | 0.150 |
Why?
| | Uromodulin | 1 | 2018 | 21 | 0.150 |
Why?
| | Genes, MHC Class II | 3 | 2012 | 74 | 0.150 |
Why?
| | Genetic Markers | 4 | 2013 | 344 | 0.150 |
Why?
| | Cholesterol | 5 | 2014 | 410 | 0.150 |
Why?
| | HLA-DP beta-Chains | 3 | 2015 | 86 | 0.140 |
Why?
| | Mexican Americans | 3 | 2014 | 120 | 0.140 |
Why?
| | Health Expenditures | 1 | 2020 | 189 | 0.140 |
Why?
| | Models, Biological | 5 | 2019 | 1783 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 257 | 0.140 |
Why?
| | Self Report | 3 | 2020 | 827 | 0.140 |
Why?
| | Squalene | 1 | 2017 | 7 | 0.140 |
Why?
| | HLA-DR2 Antigen | 2 | 2012 | 7 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.140 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 158 | 0.140 |
Why?
| | Amino Acid Sequence | 6 | 2024 | 2139 | 0.140 |
Why?
| | Antipyretics | 1 | 2017 | 5 | 0.140 |
Why?
| | Feeding Behavior | 3 | 2013 | 654 | 0.140 |
Why?
| | Cost of Illness | 1 | 2020 | 308 | 0.140 |
Why?
| | Phenotype | 8 | 2024 | 3196 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2019 | 353 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 363 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 55 | 0.130 |
Why?
| | Radioimmunoassay | 6 | 2016 | 173 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2017 | 1774 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 411 | 0.130 |
Why?
| | Body Composition | 3 | 2020 | 684 | 0.130 |
Why?
| | Rheumatoid Factor | 3 | 2007 | 175 | 0.130 |
Why?
| | Kidney Diseases | 2 | 2012 | 408 | 0.130 |
Why?
| | Rural Health | 2 | 2002 | 80 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 600 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 243 | 0.130 |
Why?
| | Genetic Loci | 3 | 2015 | 288 | 0.130 |
Why?
| | Patient Care Planning | 2 | 2015 | 157 | 0.130 |
Why?
| | Poland | 4 | 2010 | 35 | 0.130 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 59 | 0.130 |
Why?
| | Milk Proteins | 1 | 1996 | 34 | 0.130 |
Why?
| | Toxins, Biological | 1 | 2016 | 12 | 0.130 |
Why?
| | Cytokines | 4 | 2017 | 2085 | 0.130 |
Why?
| | Homozygote | 5 | 2014 | 203 | 0.130 |
Why?
| | Arachidonic Acid | 2 | 2021 | 120 | 0.130 |
Why?
| | Body Weight | 3 | 2016 | 985 | 0.130 |
Why?
| | Models, Theoretical | 2 | 2017 | 578 | 0.130 |
Why?
| | Immunoglobulin G | 4 | 2021 | 893 | 0.130 |
Why?
| | Proteins | 2 | 2021 | 1009 | 0.130 |
Why?
| | Vitamin B 12 | 1 | 2017 | 128 | 0.130 |
Why?
| | Hygiene | 1 | 2016 | 30 | 0.130 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 7 | 2006 | 47 | 0.120 |
Why?
| | HLA-A1 Antigen | 2 | 2006 | 4 | 0.120 |
Why?
| | HLA-DP Antigens | 2 | 2007 | 33 | 0.120 |
Why?
| | Diet Surveys | 4 | 2021 | 95 | 0.120 |
Why?
| | Polymerase Chain Reaction | 5 | 2011 | 1062 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 89 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 125 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Feeding Methods | 1 | 2015 | 6 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1587 | 0.120 |
Why?
| | Oxygen | 1 | 2020 | 931 | 0.120 |
Why?
| | Histocompatibility Testing | 6 | 2017 | 126 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 767 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2018 | 617 | 0.120 |
Why?
| | Stress, Psychological | 2 | 2021 | 1100 | 0.120 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 259 | 0.120 |
Why?
| | Erythrocytes | 1 | 2021 | 700 | 0.120 |
Why?
| | Medical Records | 2 | 2007 | 177 | 0.120 |
Why?
| | Dietary Fiber | 1 | 2015 | 54 | 0.120 |
Why?
| | Complement C3 | 1 | 2016 | 209 | 0.120 |
Why?
| | Carbohydrates | 1 | 2015 | 65 | 0.120 |
Why?
| | Child Day Care Centers | 1 | 2015 | 36 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 539 | 0.120 |
Why?
| | Genetic Association Studies | 4 | 2020 | 377 | 0.120 |
Why?
| | Periodontal Diseases | 1 | 2015 | 61 | 0.110 |
Why?
| | Video Recording | 2 | 2015 | 180 | 0.110 |
Why?
| | Up-Regulation | 2 | 2016 | 843 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 35 | 0.110 |
Why?
| | Gram-Positive Bacteria | 1 | 2014 | 48 | 0.110 |
Why?
| | Fructosamine | 1 | 2014 | 15 | 0.110 |
Why?
| | Gram-Negative Bacteria | 1 | 2014 | 73 | 0.110 |
Why?
| | Health Records, Personal | 1 | 2014 | 27 | 0.110 |
Why?
| | Carotid Artery Diseases | 3 | 2000 | 64 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 30 | 0.110 |
Why?
| | Dairy Products | 1 | 2014 | 36 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2015 | 297 | 0.110 |
Why?
| | Societies, Scientific | 1 | 2014 | 51 | 0.110 |
Why?
| | Acetaminophen | 1 | 2017 | 268 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2900 | 0.110 |
Why?
| | Anesthesiology | 1 | 2015 | 87 | 0.110 |
Why?
| | Renal Insufficiency | 1 | 2016 | 162 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 350 | 0.110 |
Why?
| | Bias | 1 | 2015 | 218 | 0.110 |
Why?
| | Eicosapentaenoic Acid | 1 | 2013 | 39 | 0.100 |
Why?
| | Cholesterol, Dietary | 1 | 2013 | 18 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1113 | 0.100 |
Why?
| | Eggs | 1 | 2013 | 25 | 0.100 |
Why?
| | Gene Expression | 3 | 2021 | 1502 | 0.100 |
Why?
| | Siblings | 3 | 2018 | 228 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 182 | 0.100 |
Why?
| | Creatinine | 4 | 2018 | 499 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1112 | 0.100 |
Why?
| | Epigenesis, Genetic | 3 | 2024 | 660 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 327 | 0.100 |
Why?
| | Mice | 11 | 2022 | 17787 | 0.100 |
Why?
| | Heart Rate | 3 | 2010 | 822 | 0.100 |
Why?
| | Communicable Diseases | 1 | 2015 | 159 | 0.100 |
Why?
| | Biological Specimen Banks | 1 | 2013 | 102 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Sex Characteristics | 7 | 2015 | 762 | 0.100 |
Why?
| | Monoamine Oxidase | 1 | 2012 | 30 | 0.100 |
Why?
| | Immunity, Innate | 2 | 2022 | 828 | 0.100 |
Why?
| | Research Support as Topic | 1 | 2013 | 119 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2023 | 718 | 0.100 |
Why?
| | Pilot Projects | 4 | 2023 | 1710 | 0.100 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 29 | 0.100 |
Why?
| | Organizational Innovation | 1 | 2013 | 140 | 0.100 |
Why?
| | History, 21st Century | 1 | 2013 | 213 | 0.100 |
Why?
| | Stomach | 1 | 2012 | 110 | 0.100 |
Why?
| | CpG Islands | 2 | 2023 | 157 | 0.100 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 70 | 0.090 |
Why?
| | Specimen Handling | 1 | 2013 | 183 | 0.090 |
Why?
| | Proteome | 1 | 2016 | 472 | 0.090 |
Why?
| | Interleukin-4 | 2 | 2005 | 216 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 325 | 0.090 |
Why?
| | Nuclear Family | 2 | 2009 | 54 | 0.090 |
Why?
| | Viruses | 1 | 2013 | 113 | 0.090 |
Why?
| | Intestine, Small | 2 | 2005 | 156 | 0.090 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 105 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2010 | 121 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 397 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 860 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 33 | 0.090 |
Why?
| | Intestines | 1 | 2014 | 357 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 196 | 0.090 |
Why?
| | Pedigree | 4 | 2017 | 514 | 0.090 |
Why?
| | Patient Selection | 3 | 2011 | 696 | 0.090 |
Why?
| | Gliadin | 2 | 2009 | 13 | 0.090 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 185 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1236 | 0.090 |
Why?
| | Consensus | 2 | 2024 | 683 | 0.090 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 22 | 0.090 |
Why?
| | HLA-B Antigens | 1 | 2011 | 62 | 0.090 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.090 |
Why?
| | Kidney Function Tests | 1 | 2011 | 160 | 0.090 |
Why?
| | Thyroglobulin | 3 | 2025 | 27 | 0.090 |
Why?
| | Vaccines | 1 | 2016 | 406 | 0.090 |
Why?
| | Vascular Diseases | 2 | 2013 | 243 | 0.090 |
Why?
| | Interleukin-2 | 1 | 2012 | 455 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2057 | 0.090 |
Why?
| | Weight Gain | 2 | 2011 | 519 | 0.090 |
Why?
| | Endocrine Cells | 1 | 2010 | 7 | 0.090 |
Why?
| | Food, Fortified | 1 | 2010 | 42 | 0.090 |
Why?
| | Milk, Human | 3 | 2018 | 158 | 0.080 |
Why?
| | Linkage Disequilibrium | 4 | 2015 | 268 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2013 | 421 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 209 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2012 | 372 | 0.080 |
Why?
| | Myocardial Infarction | 2 | 1994 | 1046 | 0.080 |
Why?
| | Nutrition Assessment | 2 | 2015 | 92 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 125 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2010 | 159 | 0.080 |
Why?
| | Lymphocyte Activation | 1 | 2014 | 1142 | 0.080 |
Why?
| | Family | 5 | 2018 | 671 | 0.080 |
Why?
| | Microbiota | 2 | 2014 | 762 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 558 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2002 | 1164 | 0.080 |
Why?
| | Socioeconomic Factors | 5 | 2017 | 1289 | 0.080 |
Why?
| | RNA | 1 | 2016 | 921 | 0.080 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 39 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1719 | 0.080 |
Why?
| | Quality Control | 3 | 2013 | 172 | 0.080 |
Why?
| | Pancreas | 2 | 2023 | 329 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 354 | 0.080 |
Why?
| | Homeostasis | 2 | 2010 | 621 | 0.080 |
Why?
| | Bifidobacterium | 2 | 2018 | 20 | 0.080 |
Why?
| | Sequence Analysis, DNA | 3 | 2011 | 812 | 0.080 |
Why?
| | Antigens, Viral | 2 | 2021 | 178 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 97 | 0.070 |
Why?
| | Glycemic Index | 1 | 2008 | 27 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 514 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 304 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2016 | 611 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 76 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 778 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 113 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 370 | 0.070 |
Why?
| | Telomere | 3 | 2022 | 280 | 0.070 |
Why?
| | Clinical Competence | 1 | 2015 | 1118 | 0.070 |
Why?
| | Disease Outbreaks | 2 | 1991 | 395 | 0.070 |
Why?
| | Angiotensins | 1 | 2007 | 9 | 0.070 |
Why?
| | Insulin Infusion Systems | 2 | 2017 | 394 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1809 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 298 | 0.070 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 2008 | 116 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 532 | 0.070 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.070 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.070 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.070 |
Why?
| | Antidepressive Agents | 1 | 2009 | 236 | 0.070 |
Why?
| | Pediatric Obesity | 1 | 2014 | 601 | 0.060 |
Why?
| | Physicians | 1 | 2015 | 910 | 0.060 |
Why?
| | Drug Utilization | 2 | 2017 | 169 | 0.060 |
Why?
| | Wheat Hypersensitivity | 1 | 2006 | 4 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 168 | 0.060 |
Why?
| | Datasets as Topic | 2 | 2018 | 121 | 0.060 |
Why?
| | Population Surveillance | 3 | 2020 | 482 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 33 | 0.060 |
Why?
| | Antibody Specificity | 4 | 2011 | 189 | 0.060 |
Why?
| | Apolipoprotein C-III | 1 | 2006 | 12 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 560 | 0.060 |
Why?
| | Epitope Mapping | 2 | 2024 | 62 | 0.060 |
Why?
| | Birth Order | 2 | 2004 | 14 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 15 | 0.060 |
Why?
| | Carrier State | 1 | 2006 | 67 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2005 | 46 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 27 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 434 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Metagenomics | 2 | 2019 | 169 | 0.060 |
Why?
| | Chronic Disease | 4 | 2017 | 1793 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 431 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2005 | 25 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2012 | 433 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 83 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 307 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2005 | 44 | 0.060 |
Why?
| | Protective Factors | 2 | 2015 | 93 | 0.060 |
Why?
| | Capsid Proteins | 1 | 2005 | 94 | 0.060 |
Why?
| | Fathers | 1 | 2005 | 50 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4295 | 0.060 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 45 | 0.060 |
Why?
| | Interleukin-13 | 1 | 2005 | 149 | 0.060 |
Why?
| | Registries | 7 | 2019 | 2035 | 0.060 |
Why?
| | Norway | 2 | 2019 | 43 | 0.060 |
Why?
| | CD3 Complex | 1 | 2024 | 106 | 0.060 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 56 | 0.060 |
Why?
| | Survivors | 1 | 2008 | 493 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 549 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 971 | 0.050 |
Why?
| | Cattle | 3 | 2017 | 984 | 0.050 |
Why?
| | Nutritional Status | 1 | 2007 | 350 | 0.050 |
Why?
| | Pennsylvania | 2 | 2018 | 116 | 0.050 |
Why?
| | Research Design | 3 | 2019 | 1139 | 0.050 |
Why?
| | Postmenopause | 3 | 2020 | 366 | 0.050 |
Why?
| | Anthropometry | 1 | 2004 | 213 | 0.050 |
Why?
| | Waist Circumference | 2 | 2015 | 143 | 0.050 |
Why?
| | Metagenome | 1 | 2025 | 147 | 0.050 |
Why?
| | Insulin, Isophane | 1 | 2003 | 21 | 0.050 |
Why?
| | DNA | 2 | 2011 | 1459 | 0.050 |
Why?
| | Cross-Cultural Comparison | 2 | 2015 | 86 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 329 | 0.050 |
Why?
| | International Cooperation | 3 | 2016 | 198 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 83 | 0.050 |
Why?
| | Iron, Dietary | 1 | 2023 | 22 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 336 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 79 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2005 | 259 | 0.050 |
Why?
| | Creatine | 1 | 2023 | 57 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 692 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 8 | 0.050 |
Why?
| | Markov Chains | 2 | 2020 | 126 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 343 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 117 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 435 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2019 | 16 | 0.050 |
Why?
| | Electrocardiography | 2 | 2010 | 629 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3015 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 465 | 0.050 |
Why?
| | Candida | 1 | 2022 | 38 | 0.050 |
Why?
| | Choline | 1 | 2023 | 127 | 0.050 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 13 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 506 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 310 | 0.050 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.050 |
Why?
| | Prenatal Care | 1 | 2004 | 294 | 0.050 |
Why?
| | Electrochemistry | 1 | 2021 | 78 | 0.050 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 17 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 43 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2025 | 15657 | 0.040 |
Why?
| | China | 1 | 2021 | 217 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Perception | 1 | 2023 | 359 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 144 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 109 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 114 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 186 | 0.040 |
Why?
| | Isotopes | 1 | 2020 | 33 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 786 | 0.040 |
Why?
| | Dehydroascorbic Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 142 | 0.040 |
Why?
| | Growth Charts | 1 | 2020 | 14 | 0.040 |
Why?
| | Models, Statistical | 3 | 2015 | 669 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2020 | 36 | 0.040 |
Why?
| | Antibody Diversity | 1 | 2019 | 16 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 14 | 0.040 |
Why?
| | Glucose Transporter Type 2 | 1 | 2019 | 15 | 0.040 |
Why?
| | Viral Proteins | 2 | 2006 | 342 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 109 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 175 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2006 | 708 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 25 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 195 | 0.040 |
Why?
| | Haemophilus influenzae type b | 1 | 1999 | 12 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 56 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 61 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 77 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 160 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2019 | 42 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1999 | 30 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1999 | 28 | 0.040 |
Why?
| | Depression | 1 | 2009 | 1397 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 596 | 0.040 |
Why?
| | Algorithms | 2 | 2018 | 1704 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 1999 | 45 | 0.040 |
Why?
| | Proline | 1 | 2020 | 79 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2019 | 28 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 99 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 289 | 0.040 |
Why?
| | Texas | 2 | 2014 | 244 | 0.040 |
Why?
| | Alanine | 1 | 2020 | 152 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 160 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 132 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 129 | 0.040 |
Why?
| | Maternal Behavior | 1 | 1999 | 78 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 166 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 405 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 342 | 0.040 |
Why?
| | Proteobacteria | 1 | 2018 | 15 | 0.040 |
Why?
| | Adenoviridae | 1 | 2019 | 193 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 1999 | 105 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 597 | 0.040 |
Why?
| | Firmicutes | 1 | 2018 | 19 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 50 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 305 | 0.040 |
Why?
| | Pets | 1 | 2018 | 26 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 338 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2000 | 229 | 0.040 |
Why?
| | Down-Regulation | 1 | 2021 | 657 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2018 | 17 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2018 | 56 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2018 | 79 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2020 | 198 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 250 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 411 | 0.040 |
Why?
| | Postpartum Period | 1 | 2021 | 340 | 0.040 |
Why?
| | Employment | 1 | 2020 | 178 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2828 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 171 | 0.040 |
Why?
| | Pelvic Bones | 1 | 2020 | 129 | 0.040 |
Why?
| | Apolipoprotein A-I | 1 | 1997 | 30 | 0.040 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 246 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 46 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 380 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 956 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2017 | 37 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 146 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 452 | 0.030 |
Why?
| | Bicarbonates | 1 | 2017 | 44 | 0.030 |
Why?
| | Canada | 1 | 2018 | 418 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 44 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 375 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2011 | 189 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 124 | 0.030 |
Why?
| | Galactosamine | 1 | 2016 | 3 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 165 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 67 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 499 | 0.030 |
Why?
| | Acetylglucosamine | 1 | 2016 | 13 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 353 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 318 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 335 | 0.030 |
Why?
| | Africa | 2 | 1996 | 108 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 474 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 46 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 628 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2017 | 77 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1035 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 148 | 0.030 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 14 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Anemia, Sickle Cell | 1 | 2000 | 270 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 289 | 0.030 |
Why?
| | Genetic Background | 1 | 2015 | 11 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 305 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 686 | 0.030 |
Why?
| | Quality of Life | 2 | 2024 | 2892 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 81 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1272 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 500 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 86 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 515 | 0.030 |
Why?
| | Analysis of Variance | 3 | 2010 | 1316 | 0.030 |
Why?
| | Genes | 1 | 1995 | 230 | 0.030 |
Why?
| | Florida | 1 | 2015 | 107 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 48 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 293 | 0.030 |
Why?
| | Airway Management | 1 | 2015 | 52 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 622 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 730 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 442 | 0.030 |
Why?
| | Washington | 1 | 2015 | 156 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 245 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 314 | 0.030 |
Why?
| | Insulin, Long-Acting | 2 | 2005 | 63 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 385 | 0.030 |
Why?
| | Tunica Intima | 3 | 2000 | 84 | 0.030 |
Why?
| | Hospitalization | 1 | 2004 | 2199 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 157 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 135 | 0.030 |
Why?
| | Insulin Glargine | 2 | 2005 | 84 | 0.030 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.030 |
Why?
| | Epidemiologic Factors | 1 | 2013 | 9 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 55 | 0.030 |
Why?
| | Family Characteristics | 1 | 2015 | 191 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 57 | 0.030 |
Why?
| | Base Sequence | 2 | 2011 | 2181 | 0.030 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2012 | 6 | 0.030 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2012 | 11 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 257 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2015 | 302 | 0.030 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 8 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 114 | 0.020 |
Why?
| | Niacinamide | 1 | 1993 | 82 | 0.020 |
Why?
| | California | 2 | 2004 | 431 | 0.020 |
Why?
| | S100 Proteins | 1 | 2012 | 37 | 0.020 |
Why?
| | Aging | 3 | 2000 | 1864 | 0.020 |
Why?
| | Vaccines, Inactivated | 1 | 2012 | 68 | 0.020 |
Why?
| | Biometry | 1 | 1993 | 70 | 0.020 |
Why?
| | Nurses | 1 | 2015 | 180 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 150 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.020 |
Why?
| | Nitrates | 1 | 1992 | 92 | 0.020 |
Why?
| | Genome | 1 | 2014 | 300 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2012 | 79 | 0.020 |
Why?
| | Water Supply | 1 | 1992 | 78 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 904 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2011 | 14 | 0.020 |
Why?
| | Observation | 1 | 2011 | 50 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2011 | 7 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1998 | 900 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 41 | 0.020 |
Why?
| | Potassium Channels | 1 | 2012 | 151 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2014 | 351 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 36 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2012 | 168 | 0.020 |
Why?
| | Insulinoma | 1 | 2011 | 26 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1483 | 0.020 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 23 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 145 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 820 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2668 | 0.020 |
Why?
| | Causality | 1 | 1991 | 126 | 0.020 |
Why?
| | Leptin | 1 | 2012 | 236 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2007 | 706 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2015 | 556 | 0.020 |
Why?
| | Endothelium, Vascular | 2 | 2008 | 927 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 20 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 15 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 18 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 238 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 32 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7635 | 0.020 |
Why?
| | Fetal Weight | 1 | 2009 | 56 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 34 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 513 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 91 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 146 | 0.020 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 3 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 399 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2009 | 102 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1381 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 822 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 50 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 19 | 0.020 |
Why?
| | Tunica Media | 2 | 2000 | 38 | 0.020 |
Why?
| | Survival Rate | 2 | 2006 | 1972 | 0.020 |
Why?
| | Protein Precursors | 1 | 2009 | 134 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 139 | 0.020 |
Why?
| | Telecommunications | 1 | 1988 | 21 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2008 | 28 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 198 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 37 | 0.020 |
Why?
| | Outpatients | 1 | 1992 | 396 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 976 | 0.020 |
Why?
| | Pacific Islands | 1 | 1988 | 3 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 109 | 0.020 |
Why?
| | Solanum tuberosum | 1 | 2008 | 7 | 0.020 |
Why?
| | Probability | 1 | 1989 | 304 | 0.020 |
Why?
| | Americas | 1 | 1988 | 28 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 94 | 0.020 |
Why?
| | Asia | 1 | 1988 | 71 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 2009 | 123 | 0.020 |
Why?
| | Survival | 1 | 2007 | 38 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 21 | 0.020 |
Why?
| | Carotenoids | 1 | 2007 | 43 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 157 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 180 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 52 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1738 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2006 | 68 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 58 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2006 | 57 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2006 | 57 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1430 | 0.020 |
Why?
| | Serotyping | 1 | 2005 | 32 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2006 | 343 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 380 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2013 | 2833 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 32 | 0.010 |
Why?
| | Species Specificity | 1 | 2006 | 585 | 0.010 |
Why?
| | Cause of Death | 2 | 2002 | 434 | 0.010 |
Why?
| | Genome, Viral | 1 | 2005 | 144 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2005 | 128 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2004 | 10811 | 0.010 |
Why?
| | Puerto Rico | 1 | 2004 | 53 | 0.010 |
Why?
| | Ultrasonography | 2 | 2000 | 759 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 363 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 191 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 115 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 641 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2003 | 97 | 0.010 |
Why?
| | Regeneration | 1 | 2005 | 197 | 0.010 |
Why?
| | Insulin Lispro | 1 | 2003 | 39 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 282 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 3958 | 0.010 |
Why?
| | DNA, Viral | 1 | 2005 | 364 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2167 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2005 | 275 | 0.010 |
Why?
| | Duodenum | 1 | 2003 | 78 | 0.010 |
Why?
| | Health | 1 | 2003 | 84 | 0.010 |
Why?
| | Income | 1 | 2003 | 202 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 55 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 202 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4193 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 73 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1985 | 468 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 42 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 272 | 0.010 |
Why?
| | Carotid Artery, Common | 1 | 2000 | 36 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 1999 | 5 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1007 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1999 | 77 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5079 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1999 | 175 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 1999 | 203 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1998 | 148 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 269 | 0.010 |
Why?
| | Demography | 1 | 1998 | 291 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1167 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2607 | 0.010 |
Why?
| | Quantitative Trait, Heritable | 1 | 1997 | 125 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 1998 | 365 | 0.010 |
Why?
| | Bacterial Infections | 1 | 1998 | 250 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 417 | 0.010 |
Why?
| | Mexico | 1 | 1996 | 225 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 2486 | 0.010 |
Why?
| | Mental Disorders | 1 | 2002 | 1077 | 0.010 |
Why?
| | Baltic States | 1 | 1992 | 1 | 0.010 |
Why?
| | Computer Simulation | 1 | 1997 | 978 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1998 | 922 | 0.010 |
Why?
| | Rats | 1 | 2000 | 5647 | 0.010 |
Why?
| | Geography | 1 | 1992 | 200 | 0.010 |
Why?
| | Software | 1 | 1997 | 665 | 0.010 |
Why?
| | Cohort Effect | 1 | 1990 | 5 | 0.010 |
Why?
| | Periodicity | 1 | 1990 | 58 | 0.010 |
Why?
| | Space-Time Clustering | 1 | 1989 | 4 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1989 | 27 | 0.000 |
Why?
| | Coxsackievirus Infections | 1 | 1987 | 14 | 0.000 |
Why?
| | Rubella | 1 | 1987 | 24 | 0.000 |
Why?
| | Mortality | 1 | 1989 | 362 | 0.000 |
Why?
| | Neoplasms | 1 | 1989 | 2671 | 0.000 |
Why?
|
|
Rewers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|